Edesa Biotech, Inc. (NASDAQ: EDSA) Stock Competitors & Peer Comparison
See EDSA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EDSA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EDSA | $2.14 | +0.47% | 20.7M | -1.27 | -$1.69 | N/A |
| VRTX | $547.09 | +0.85% | 138.6B | 28.74 | $19.03 | N/A |
| MRNA | $254.19 | +5.27% | 101.5B | -31.20 | -$8.15 | N/A |
| REGN | $904.35 | +0.16% | 93.6B | 19.82 | $45.63 | +0.41% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $927.21 | +3.63% | 55.3B | 33.44 | $27.73 | N/A |
| ONC | $406.96 | +5.09% | 43.5B | 71.66 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.90 | +16.47% | 41.4B | -1.12 | -$8.82 | N/A |
| RVMD | $192.28 | +8.24% | 41.2B | -21.79 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
EDSA vs VRTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while VRTX trades at $547.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas VRTX's P/E ratio is 28.74. In terms of profitability, EDSA's ROE is -1.24%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, EDSA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
EDSA vs MRNA Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MRNA has a market cap of 101.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MRNA trades at $254.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MRNA's P/E ratio is -31.20. In terms of profitability, EDSA's ROE is -1.24%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, EDSA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
EDSA vs REGN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, REGN has a market cap of 93.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while REGN trades at $904.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas REGN's P/E ratio is 19.82. In terms of profitability, EDSA's ROE is -1.24%, compared to REGN's ROE of +0.15%. Regarding short-term risk, EDSA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
EDSA vs VRNA Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas VRNA's P/E ratio is -102.80. In terms of profitability, EDSA's ROE is -1.24%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, EDSA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
EDSA vs ARGX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ARGX trades at $927.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ARGX's P/E ratio is 33.44. In terms of profitability, EDSA's ROE is -1.24%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, EDSA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
EDSA vs ONC Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ONC has a market cap of 43.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ONC trades at $406.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ONC's P/E ratio is 71.66. In terms of profitability, EDSA's ROE is -1.24%, compared to ONC's ROE of +0.18%. Regarding short-term risk, EDSA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
EDSA vs SGEN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EDSA's ROE is -1.24%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EDSA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
EDSA vs RVMDW Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RVMDW has a market cap of 41.4B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RVMDW trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, EDSA's ROE is -1.24%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, EDSA is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
EDSA vs RVMD Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RVMD has a market cap of 41.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RVMD trades at $192.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RVMD's P/E ratio is -21.79. In terms of profitability, EDSA's ROE is -1.24%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, EDSA is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RVMD's competition here
Genmab A/S (NASDAQ: GMAB)
EDSA vs GMAB Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, GMAB has a market cap of 33B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while GMAB trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas GMAB's P/E ratio is 40.41. In terms of profitability, EDSA's ROE is -1.24%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, EDSA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
EDSA vs ROIV Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ROIV has a market cap of 28.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ROIV trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ROIV's P/E ratio is -37.00. In terms of profitability, EDSA's ROE is -1.24%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, EDSA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
EDSA vs INSM Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while INSM trades at $114.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas INSM's P/E ratio is -40.59. In terms of profitability, EDSA's ROE is -1.24%, compared to INSM's ROE of -0.83%. Regarding short-term risk, EDSA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
EDSA vs INCY Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while INCY trades at $119.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas INCY's P/E ratio is 16.08. In terms of profitability, EDSA's ROE is -1.24%, compared to INCY's ROE of +0.07%. Regarding short-term risk, EDSA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
EDSA vs UTHR Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while UTHR trades at $562.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas UTHR's P/E ratio is 20.11. In terms of profitability, EDSA's ROE is -1.24%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EDSA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check UTHR's competition here
BioNTech SE (NASDAQ: BNTX)
EDSA vs BNTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while BNTX trades at $87.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas BNTX's P/E ratio is -11.35. In terms of profitability, EDSA's ROE is -1.24%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, EDSA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
EDSA vs ALNY Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ALNY has a market cap of 20.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ALNY trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ALNY's P/E ratio is 7.87. In terms of profitability, EDSA's ROE is -1.24%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, EDSA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
EDSA vs BGNE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EDSA's ROE is -1.24%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, EDSA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
EDSA vs DNA-WT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EDSA's ROE is -1.24%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, EDSA is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
EDSA vs EXEL Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, EXEL has a market cap of 17.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while EXEL trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas EXEL's P/E ratio is 19.87. In terms of profitability, EDSA's ROE is -1.24%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, EDSA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
EDSA vs ASND Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ASND has a market cap of 16.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ASND trades at $256.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ASND's P/E ratio is -106.12. In terms of profitability, EDSA's ROE is -1.24%, compared to ASND's ROE of +1.90%. Regarding short-term risk, EDSA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
EDSA vs NBIX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while NBIX trades at $164.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas NBIX's P/E ratio is 23.79. In terms of profitability, EDSA's ROE is -1.24%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, EDSA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
EDSA vs JAZZ Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while JAZZ trades at $234.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas JAZZ's P/E ratio is 8.75. In terms of profitability, EDSA's ROE is -1.24%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, EDSA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
EDSA vs BBIO Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, BBIO has a market cap of 14.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while BBIO trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas BBIO's P/E ratio is -24.43. In terms of profitability, EDSA's ROE is -1.24%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, EDSA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
EDSA vs SMMT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, SMMT has a market cap of 13B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while SMMT trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas SMMT's P/E ratio is -14.58. In terms of profitability, EDSA's ROE is -1.24%, compared to SMMT's ROE of -1.59%. Regarding short-term risk, EDSA is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
EDSA vs KRTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EDSA's ROE is -1.24%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EDSA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
EDSA vs HALO Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, HALO has a market cap of 11.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while HALO trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas HALO's P/E ratio is 19.35. In terms of profitability, EDSA's ROE is -1.24%, compared to HALO's ROE of +5.44%. Regarding short-term risk, EDSA is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
EDSA vs TECH Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while TECH trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas TECH's P/E ratio is 37.52. In terms of profitability, EDSA's ROE is -1.24%, compared to TECH's ROE of +0.09%. Regarding short-term risk, EDSA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
EDSA vs RNAM Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RNAM's P/E ratio is -17.39. In terms of profitability, EDSA's ROE is -1.24%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, EDSA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
EDSA vs KYMR Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, KYMR has a market cap of 11.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while KYMR trades at $131.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas KYMR's P/E ratio is -36.38. In terms of profitability, EDSA's ROE is -1.24%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, EDSA is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check KYMR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
EDSA vs BMRN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while BMRN trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas BMRN's P/E ratio is 26.93. In terms of profitability, EDSA's ROE is -1.24%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, EDSA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check BMRN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
EDSA vs PCVX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while PCVX trades at $63.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas PCVX's P/E ratio is -8.37. In terms of profitability, EDSA's ROE is -1.24%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, EDSA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
EDSA vs SYRE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, SYRE has a market cap of 9.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while SYRE trades at $103.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas SYRE's P/E ratio is -53.26. In terms of profitability, EDSA's ROE is -1.24%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, EDSA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check SYRE's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
EDSA vs RXDX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EDSA's ROE is -1.24%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EDSA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RXDX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
EDSA vs MDGL Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MDGL trades at $399.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MDGL's P/E ratio is -31.27. In terms of profitability, EDSA's ROE is -1.24%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, EDSA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check MDGL's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
EDSA vs TGTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, TGTX has a market cap of 9.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while TGTX trades at $59.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas TGTX's P/E ratio is 21.68. In terms of profitability, EDSA's ROE is -1.24%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, EDSA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
EDSA vs IBRX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while IBRX trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas IBRX's P/E ratio is -8.90. In terms of profitability, EDSA's ROE is -1.24%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, EDSA is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
EDSA vs NUVL Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas NUVL's P/E ratio is -21.79. In terms of profitability, EDSA's ROE is -1.24%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, EDSA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
EDSA vs CRNX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CRNX's P/E ratio is -16.86. In terms of profitability, EDSA's ROE is -1.24%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, EDSA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CRNX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
EDSA vs KRYS Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while KRYS trades at $300.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas KRYS's P/E ratio is 37.68. In terms of profitability, EDSA's ROE is -1.24%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, EDSA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check KRYS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
EDSA vs IMGN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EDSA's ROE is -1.24%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, EDSA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
EDSA vs PTGX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while PTGX trades at $132.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas PTGX's P/E ratio is 128.05. In terms of profitability, EDSA's ROE is -1.24%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, EDSA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
EDSA vs APGE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas APGE's P/E ratio is -31.19. In terms of profitability, EDSA's ROE is -1.24%, compared to APGE's ROE of -0.30%. Regarding short-term risk, EDSA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
EDSA vs BPMC Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas BPMC's P/E ratio is -51.58. In terms of profitability, EDSA's ROE is -1.24%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, EDSA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check BPMC's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
EDSA vs ARWR Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ARWR trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ARWR's P/E ratio is -25.84. In terms of profitability, EDSA's ROE is -1.24%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, EDSA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
EDSA vs CERE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CERE's P/E ratio is -16.47. In terms of profitability, EDSA's ROE is -1.24%, compared to CERE's ROE of -0.72%. Regarding short-term risk, EDSA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
EDSA vs TWST Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, TWST has a market cap of 8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while TWST trades at $120.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas TWST's P/E ratio is -54.47. In terms of profitability, EDSA's ROE is -1.24%, compared to TWST's ROE of -0.30%. Regarding short-term risk, EDSA is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check TWST's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
EDSA vs PRAX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while PRAX trades at $277.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas PRAX's P/E ratio is -21.49. In terms of profitability, EDSA's ROE is -1.24%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, EDSA is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check PRAX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
EDSA vs RYTM Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RYTM has a market cap of 7.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RYTM trades at $112.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RYTM's P/E ratio is -36.07. In terms of profitability, EDSA's ROE is -1.24%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, EDSA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RYTM's competition here
Abivax S.A. (NASDAQ: ABVX)
EDSA vs ABVX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ABVX trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ABVX's P/E ratio is -14.06. In terms of profitability, EDSA's ROE is -1.24%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, EDSA is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ABVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
EDSA vs CYTK Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CYTK trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CYTK's P/E ratio is -7.44. In terms of profitability, EDSA's ROE is -1.24%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, EDSA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
EDSA vs MTSR Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MTSR's P/E ratio is -23.58. In terms of profitability, EDSA's ROE is -1.24%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, EDSA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
EDSA vs CAI Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CAI trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CAI's P/E ratio is 70.92. In terms of profitability, EDSA's ROE is -1.24%, compared to CAI's ROE of +0.16%. Regarding short-term risk, EDSA is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check CAI's competition here
10x Genomics, Inc. (NASDAQ: TXG)
EDSA vs TXG Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, TXG has a market cap of 7.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while TXG trades at $59.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas TXG's P/E ratio is -100.53. In terms of profitability, EDSA's ROE is -1.24%, compared to TXG's ROE of -0.08%. Regarding short-term risk, EDSA is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check TXG's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
EDSA vs AXSM Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, AXSM has a market cap of 7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while AXSM trades at $132.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas AXSM's P/E ratio is -34.56. In terms of profitability, EDSA's ROE is -1.24%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, EDSA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check AXSM's competition here
Merus N.V. (NASDAQ: MRUS)
EDSA vs MRUS Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MRUS's P/E ratio is -17.05. In terms of profitability, EDSA's ROE is -1.24%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, EDSA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
EDSA vs ORKA Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ORKA trades at $102.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ORKA's P/E ratio is -52.98. In terms of profitability, EDSA's ROE is -1.24%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, EDSA is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
EDSA vs CGON Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CGON trades at $75.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CGON's P/E ratio is -28.25. In terms of profitability, EDSA's ROE is -1.24%, compared to CGON's ROE of -0.19%. Regarding short-term risk, EDSA is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check CGON's competition here
Arcellx, Inc. (NASDAQ: ACLX)
EDSA vs ACLX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ACLX's P/E ratio is -28.27. In terms of profitability, EDSA's ROE is -1.24%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, EDSA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
EDSA vs RETA Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RETA's P/E ratio is -66.29. In terms of profitability, EDSA's ROE is -1.24%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EDSA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RETA's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
EDSA vs IONS Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while IONS trades at $39.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas IONS's P/E ratio is -12.05. In terms of profitability, EDSA's ROE is -1.24%, compared to IONS's ROE of -1.11%. Regarding short-term risk, EDSA is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
EDSA vs IMVT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while IMVT trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas IMVT's P/E ratio is -10.82. In terms of profitability, EDSA's ROE is -1.24%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, EDSA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check IMVT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
EDSA vs CNTA Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CNTA's P/E ratio is -22.63. In terms of profitability, EDSA's ROE is -1.24%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, EDSA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
EDSA vs KOD Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while KOD trades at $99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas KOD's P/E ratio is -23.82. In terms of profitability, EDSA's ROE is -1.24%, compared to KOD's ROE of -2.73%. Regarding short-term risk, EDSA is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
EDSA vs BLTE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while BLTE trades at $154.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas BLTE's P/E ratio is -82.52. In terms of profitability, EDSA's ROE is -1.24%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, EDSA is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
EDSA vs LGND Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while LGND trades at $306.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas LGND's P/E ratio is 33.58. In terms of profitability, EDSA's ROE is -1.24%, compared to LGND's ROE of +0.05%. Regarding short-term risk, EDSA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check LGND's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
EDSA vs TERN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas TERN's P/E ratio is -51.41. In terms of profitability, EDSA's ROE is -1.24%, compared to TERN's ROE of -0.14%. Regarding short-term risk, EDSA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check TERN's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
EDSA vs MIRM Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MIRM trades at $93.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MIRM's P/E ratio is -6.44. In terms of profitability, EDSA's ROE is -1.24%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, EDSA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
EDSA vs MANE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MANE trades at $138.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MANE's P/E ratio is -44.17. In terms of profitability, EDSA's ROE is -1.24%, compared to MANE's ROE of -0.38%. Regarding short-term risk, EDSA is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check MANE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
EDSA vs SRRK Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while SRRK trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas SRRK's P/E ratio is -13.60. In terms of profitability, EDSA's ROE is -1.24%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, EDSA is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
EDSA vs CDTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CDTX's P/E ratio is -19.77. In terms of profitability, EDSA's ROE is -1.24%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, EDSA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
EDSA vs ABCM Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EDSA's ROE is -1.24%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EDSA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
EDSA vs ISEE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EDSA's ROE is -1.24%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EDSA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
EDSA vs COGT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while COGT trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas COGT's P/E ratio is -15.00. In terms of profitability, EDSA's ROE is -1.24%, compared to COGT's ROE of -0.71%. Regarding short-term risk, EDSA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
EDSA vs PTCT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while PTCT trades at $65.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas PTCT's P/E ratio is -46.74. In terms of profitability, EDSA's ROE is -1.24%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, EDSA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
EDSA vs APLS Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas APLS's P/E ratio is 38.35. In terms of profitability, EDSA's ROE is -1.24%, compared to APLS's ROE of +0.40%. Regarding short-term risk, EDSA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
EDSA vs ERAS Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ERAS trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ERAS's P/E ratio is -15.49. In terms of profitability, EDSA's ROE is -1.24%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, EDSA is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check ERAS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
EDSA vs CRSP Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CRSP trades at $50.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CRSP's P/E ratio is -10.52. In terms of profitability, EDSA's ROE is -1.24%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, EDSA is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
EDSA vs EWTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while EWTX trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas EWTX's P/E ratio is -24.37. In terms of profitability, EDSA's ROE is -1.24%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, EDSA is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check EWTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
EDSA vs DNTH Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, DNTH has a market cap of 4.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while DNTH trades at $86.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas DNTH's P/E ratio is -20.72. In terms of profitability, EDSA's ROE is -1.24%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, EDSA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
EDSA vs TVTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas TVTX's P/E ratio is -110.27. In terms of profitability, EDSA's ROE is -1.24%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, EDSA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
EDSA vs FOLD Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas FOLD's P/E ratio is -161.00. In terms of profitability, EDSA's ROE is -1.24%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, EDSA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
EDSA vs AKRO Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas AKRO's P/E ratio is -14.57. In terms of profitability, EDSA's ROE is -1.24%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, EDSA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check AKRO's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
EDSA vs DFTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while DFTX trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas DFTX's P/E ratio is N/A. In terms of profitability, EDSA's ROE is -1.24%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, EDSA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check DFTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
EDSA vs ADPT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ADPT trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ADPT's P/E ratio is -68.20. In terms of profitability, EDSA's ROE is -1.24%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, EDSA is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
EDSA vs ALPN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EDSA's ROE is -1.24%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, EDSA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ALPN's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
EDSA vs LEGN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while LEGN trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas LEGN's P/E ratio is -34.41. In terms of profitability, EDSA's ROE is -1.24%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, EDSA is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check LEGN's competition here
Opthea Limited (NASDAQ: OPT)
EDSA vs OPT Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas OPT's P/E ratio is -1.52. In terms of profitability, EDSA's ROE is -1.24%, compared to OPT's ROE of +1.18%. Regarding short-term risk, EDSA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
EDSA vs PRTC Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas PRTC's P/E ratio is -3.78. In terms of profitability, EDSA's ROE is -1.24%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, EDSA is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
EDSA vs MRTX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EDSA's ROE is -1.24%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EDSA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
EDSA vs RLAY Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RLAY trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RLAY's P/E ratio is -11.85. In terms of profitability, EDSA's ROE is -1.24%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, EDSA is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check RLAY's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
EDSA vs CPRX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CPRX's P/E ratio is 17.49. In terms of profitability, EDSA's ROE is -1.24%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, EDSA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
EDSA vs ABCL Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ABCL trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ABCL's P/E ratio is -22.01. In terms of profitability, EDSA's ROE is -1.24%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, EDSA is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ABCL's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
EDSA vs XENE Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while XENE trades at $39.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas XENE's P/E ratio is -8.34. In terms of profitability, EDSA's ROE is -1.24%, compared to XENE's ROE of -0.44%. Regarding short-term risk, EDSA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
EDSA vs RYZB Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EDSA's ROE is -1.24%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EDSA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
EDSA vs CBAY Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EDSA's ROE is -1.24%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EDSA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
EDSA vs AMLX Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while AMLX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas AMLX's P/E ratio is -19.68. In terms of profitability, EDSA's ROE is -1.24%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, EDSA is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check AMLX's competition here
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
EDSA vs ACAD Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ACAD trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ACAD's P/E ratio is 9.56. In terms of profitability, EDSA's ROE is -1.24%, compared to ACAD's ROE of +0.28%. Regarding short-term risk, EDSA is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
EDSA vs IOVA Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while IOVA trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas IOVA's P/E ratio is -11.01. In terms of profitability, EDSA's ROE is -1.24%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, EDSA is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for EDSA.Check IOVA's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
EDSA vs ELVN Comparison November 2026
Edesa Biotech, Inc. (NASDAQ: EDSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EDSA stands at 20.7M. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, EDSA is priced at $2.14 on the NASDAQ, while ELVN trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EDSA currently has a P/E ratio of -1.27, whereas ELVN's P/E ratio is -29.63. In terms of profitability, EDSA's ROE is -1.24%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, EDSA is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for EDSA.Check ELVN's competition here